Health
Trial testing anti-coronavirus hIVIG plus remdesivir in COVID-19 patients – European Pharmaceutical Review
The ITAC trial will establish if hyperimmune intravenous immunoglobulin (hIVIG) plus remdesivir can improve COVID-19 patient outcomes.
Posted: 9 October 2020 | Hannah Balfour (European Pharmaceutical Review) | No comments yet
The ITAC trial will establish if adding hyperimmune intravenous immunoglobulin (hIVIG) to a remdesivir regimen can improve hospitalised COVID-19 patient outcomes.
A Phase III trial to evaluate the safety, tolerability and efficacy of a combination of the antiviral remdesivir and a highly concentrated solution of SARS-CoV-2 neutralising antibodies in hospitalised adult COVID-19 patients has begun.
The tr…
-
General22 hours agoMaría Corina Machado awarded Nobel Peace Prize
-
General21 hours agoDonald Trump didn’t receive the Nobel Peace Prize. Experts say he had ‘no chance’ at winning
-
Noosa News21 hours agoQueensland’s bid for net zero by 2050 unlikely under new energy plan: expert
-
General19 hours agoWestern Bulldogs extend Essendon’s losing streak with 57 point thrashing